Skip to content

Drug interactions

Brigatinib + Efavirenz

Severity: Major

Brigatinib and Efavirenz: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Efavirenz can lower brigatinib exposure through CYP3A induction, potentially reducing its anti-tumor effect in ALK-positive lung cancer.

What this interaction means in plain words

Brigatinib and Efavirenz can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Brigatinib belongs to Oncology; Efavirenz belongs to Anti Virals.

Evidence level: Moderate

Why it happens

Efavirenz induces CYP3A4, accelerating brigatinib metabolism.

What to do

Avoid the combination and use a non-inducing antiretroviral. If a strong or moderate inducer is unavoidable, the brigatinib dose may need to be increased per labeling with close monitoring of response and tolerability.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Brigatinib and Efavirenz, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Brigatinib with Efavirenz?

MediHelp rates the interaction as major. Brigatinib and Efavirenz can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Efavirenz can lower brigatinib exposure through CYP3A induction, potentially reducing its anti-tumor effect in ALK-positive lung cancer.

How serious is the interaction between Brigatinib and Efavirenz?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and use a non-inducing antiretroviral. If a strong or moderate inducer is unavoidable, the brigatinib dose may need to be increased per labeling with close monitoring of response and tolerability.

What other medicines interact with Efavirenz?

MediHelp also lists interactions of Efavirenz with, for example, Cobimetinib, Dienogest / estradiol valerate, Dihydroergotamine intranasal. The full list is on the Efavirenz page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in